Central Hospital of Kaifeng

Kaifeng, China

Central Hospital of Kaifeng

Kaifeng, China
SEARCH FILTERS
Time filter
Source Type

Gan J.,Shantou University | Zhang Y.,Shantou University | Ke X.,Shantou University | Tan C.,Sun Yat Sen University | And 6 more authors.
International Journal of Molecular Sciences | Year: 2015

Primary esophageal small cell carcinoma (PESCC) is a rare, but fatal subtype of esophageal carcinoma. No effective therapeutic regimen for it. P21-activated kinase 1 (PAK1) is known to function as an integrator and an indispensable node of major growth factor signaling and the molecular therapy targeting PAK1 has been clinical in pipeline. We thus set to examine the expression and clinical impact of PAK1 in PESCC. The expression of PAK1 was detected in a semi-quantitative manner by performing immunohistochemistry. PAK1 was overexpressed in 22 of 34 PESCC tumors, but in only 2 of 18 adjacent non-cancerous tissues. Overexpression of PAK1 was significantly associated with tumor location (p = 0.011), lymph node metastasis (p = 0.026) and patient survival (p = 0.032). We also investigated the association of PAK1 with DNA damage, a driven cause for malignancy progression. γH2AX, a DNA damage marker, was detectable in 18 of 24 (75.0%) cases, and PAK1 expression was associated with γH2AX (p = 0.027). Together, PAK1 is important in metastasis and progression of PESCC. The contribution of PAK1 to clinical outcomes may be involved in its regulating DNA damage pathway. Further studies are worth determining the potentials of PAK1 as prognostic indicator and therapeutic target for PESCC. © 2015 by the authors; licensee MDPI, Basel, Switzerland.


PubMed | Central Hospital of Kaifeng, Sun Yat Sen University and Shantou University
Type: Journal Article | Journal: International journal of molecular sciences | Year: 2015

Primary esophageal small cell carcinoma (PESCC) is a rare, but fatal subtype of esophageal carcinoma. No effective therapeutic regimen for it. P21-activated kinase 1 (PAK1) is known to function as an integrator and an indispensable node of major growth factor signaling and the molecular therapy targeting PAK1 has been clinical in pipeline. We thus set to examine the expression and clinical impact of PAK1 in PESCC. The expression of PAK1 was detected in a semi-quantitative manner by performing immunohistochemistry. PAK1 was overexpressed in 22 of 34 PESCC tumors, but in only 2 of 18 adjacent non-cancerous tissues. Overexpression of PAK1 was significantly associated with tumor location (p = 0.011), lymph node metastasis (p = 0.026) and patient survival (p = 0.032). We also investigated the association of PAK1 with DNA damage, a driven cause for malignancy progression. H2AX, a DNA damage marker, was detectable in 18 of 24 (75.0%) cases, and PAK1 expression was associated with H2AX (p = 0.027). Together, PAK1 is important in metastasis and progression of PESCC. The contribution of PAK1 to clinical outcomes may be involved in its regulating DNA damage pathway. Further studies are worth determining the potentials of PAK1 as prognostic indicator and therapeutic target for PESCC.


Gao L.,Central Hospital of Kaifeng | Xu Z.-Q.,Central Hospital of Kaifeng | Yi Z.-Y.,Central Hospital of Kaifeng | Gao X.,Central Hospital of Kaifeng
Cancer Research and Clinic | Year: 2013

Objective: To compare the efficacy for aged patients with locally advanced esophageal cancer who accepted 3D-CRT with or without S-1. Methods: 62 aged patients with locally advanced esophageal cancer were randomized divided into three groups in Central Hospital of Kaifeng since March, 2009. The S-1 combined with radiotherapy group was 26 patients as combined group, the single radiotherapy group was 20 patients and single drug group was 16 patients. S-1 combined group patients accepted 3D-CRT, and the patients were taken S-1 from the first day, the dose was 40 mg/m2 twice a day continually 14 days and then stop 7 days. There were 2 cycles during radiotherapy. The 20 patients accepted 3D-CRT in single radiotherapy group, and the patients in single drug group were taken S-1 only, the dose was 40 mg/m2 twice a day continually 28 days and then stop 14 days within 28 days. Results: The response rate was 92.31% in S-1 combined group, with 13 patients CR, 11 patients PR, and 1 patient SD. The response rate was 60.00% in single radiotherapy group, with 4 patients CR, 8 patients PR and 6 patients SD. The response rate was 31.25% in single drug group, with 1 patients CR, 4 patients PR and 6 patients SD. The effect of the S-1 combined with radiotherapy group was significant better than the others (P < 0.05). The 1, 2 and 3 year survival rates in each group were 76.92%, 57.69%, 42.31%, 75.00%, 55.00%, 40.00% and 68.75%, 50.00%, 25.00%, which there is no significant difference in the three groups. The adverse reaction of hematologic toxicity in S-1 combined with radiotherapy group was little higher than the others, still there was no significant difference in the incidence rate of radiation esophagitis and radiation pneumonitis between S-1 combined with radiotherapy group and single radiotherapy group. Conclusion S-1 plus three dimensional conformal radiotherapy treatments were reliable, and the adverse reactions were mild and well tolerated for elderly patients with locally advanced esophageal cancer.


Gao L.,Central Hospital of Kaifeng | Song Z.-B.,Central Hospital of Kaifeng | Li N.,Central Hospital of Kaifeng | Xu Z.-Q.,Central Hospital of Kaifeng
Chinese Journal of Cancer Prevention and Treatment | Year: 2015

OBJECTIVE: To research the value of re-course radiotherapy for local recurrence of esophageal cancer after radiotherapy, and analyze the curative effect and adverse reactions of re-course radiotherapy and radiotherapy combined with chemotherapy. METHODS: The curative effect and adverse reactions of 20 patients with re-course radiotherapy and 21 patients with radiotherapy combined with chemotherapy were compared retrospectively. RESULTS: The RR of recurrence in the re-course radiotherapy group was 45.00%(9/20), while 85.71%(18/21) in the radiotherapy combined with chemotherapy. There was statistically difference between the two groups (χ2= 8.25, P=0.035). The 1-, 2- and 3-year survival rates were 45.00%(9/20), 25.00%(5/20) and 10.00%(2/20) in the simple re-course radiotherapy group, while 52.38%(11/21), 28.57%(6/21), 14.29%(3/21) in the group of radiotherapy combined with chemotherapy. There was not statistically difference between the two groups (χ2=0.05, P=0.975). Both treatment types were well-tolerated. As for adverse reactions, the acute radiation-induced esophagitis rate in the re-course radiotherapy group was 75.00%(15/20), in which ≥Grade 2 was 45.00%(9/20), and 90.45%(13/20) in the group of radiotherapy combined with chemotherapy, in which ≥Grade 2 was 52.39%(11/21). There was not statistically difference between the two groups (z=-0.877, P=0.380). In addition, the acute radiation-induced pneumonitis rate was 20.00%(4/20), in which ≥Grade 2 was 5.00%(1/20), and 23.81%(5/21), in which ≥Grade 2 was 45.00%(9/20). There was not statistically difference between the two groups (z=-0.361, P=0.718). Moreover, the myelosuppression rate was 9. 52%(2/21), in which ≥Grade 2 was 5.00%(1/20), and 57.14%(12/21), in which ≥Grade 2 was 23.81%(5/20). There was not statistically difference between the two groups(z=-1.228, P=0.220). CONCLUSIONS: Re-course radiotherapy is an effective treatment for local recurrences of esophageal cancer, and can be used in combination with chemotherapy to improve the treatment. Adverse reactions of both treatment forms were minimal. ©, 2015, The Editorial Board of Chinese Journal of Cancer Prevention and Treatment. All right reserved.

Loading Central Hospital of Kaifeng collaborators
Loading Central Hospital of Kaifeng collaborators